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Background: Peripheral vascular disease of the lower extremities comprises a clinical spectrum that extends from
no symptoms to presentation with critical limb ischemia (CLI). Bone marrow derived Mesenchymal Stem Cells
(BM- MSCs) may ameliorate the consequences of CLI due to their combinatorial potential for inducing angiogenesis
and immunomodulatory environment in situ. The primary objective was to determine the safety of BM- MSCs in
patients with CLI.
Methods: Prospective, double blind randomized placebo controlled multi-center study was conducted in patients
with established CLI as per Rutherford classification in category II-4, III-5, or III-6 with infra-inguinal arterial occlusive
disease and were not suitable for or had failed revascularization treatment. The primary end point was incidence of
treatment – related adverse events (AE). Exploratory efficacy end points were improvement in rest pain, increase in
Ankle Brachial Pressure Index (ABPI), ankle pressure, healing of ulcers, and amputation rates. Twenty patients
(BM-MSC: Placebo = 1:1) were administered with allogeneic BM-MSCs at a dose of 2 million cells/kg or placebo
(PlasmaLyte A) at the gastrocnemius muscle of the ischemic limb.
Results: Improvement was observed in the rest pain scores in both the arms. Significant increase in ABPI and ankle
pressure was seen in BM-MSC arm compared to the placebo group. Incidence of AEs in the BM-MSC arm was 13
vs. 45 in the placebo arm where as serious adverse events (SAE) were similar in both the arms (5 in BM-MSC and 4
in the placebo group). SAEs resulted in death, infected gangrene, amputations in these patients. It was observed
that the SAEs were related to disease progression and not related to stem cells.
Conclusion: BM-MSCs are safe when injected IM at a dose of 2 million cells/kg body weight. Few efficacy
parameters such as ABPI and ankle pressure showed positive trend warranting further studies.
Trial registration: NIH website (http://www.clinicaltrials.gov/ct2/show/NCT00883870)
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Peripheral vascular disease of the lower extremities com-
prises a clinical spectrum that extends from asymptomatic
disease to presentation with critical limb ischemia (CLI).
The incidence of CLI is estimated to be approximately
500 to 1000 patients per million per year [1]. Critical Limb
ischemia has been defined as a condition where there is
rest pain, or tissue necrosis with ulcers or gangrene in a
setting of proven peripheral arterial occlusive disease [2],
with an absolute ankle pressure of ≤ 70 mmHg or a toe
systolic pressure of ≤ 50 mmHg [3]. About 50% patients
with CLI will lose their leg within 6 – 12 months, and ap-
proximately 15% will require contralateral amputation
within 2 years with one year mortality rate as high as 20%
and subsequently rising to 70% and 100% at 5 and 10 years
respectively [4].
Transplantation of autologous bone marrow – derived
mononuclear cells (BM-MNCs) has been shown to
induce neo – vascularization of ischemic tissue which
introduced the concept of postnatal vasculogenesis [5,6].
Several clinical studies have shown that a variety of
progenitor cell types, delivered locally by intramuscular
route or systemically by intra-arterial route into the
ischemic tissue exert therapeutic benefits [7-10]. More
recently, using Ixmyelocel-T, an autologous expanded
multicellular mixture from bone marrow, Powell et al.
have demonstrated significant prolongation of time to
first occurrence of treatment failure (TTF) and clinically
meaningful but not significant amputation free survival
time compared to the placebo treatment [11].
Bone marrow derived mesenchymal stem cells (BM-
MSCs) are multipotent and differentiate easily to alternate
lineages such as osteocytes, chondrocytes, adipocytes, neu-
rons, skeletal muscle cells, endothelial cells and vascular
smooth muscle cells [12-14]. BM-MSC can be expanded
many folds in vitro and it is easy to obtain sufficient num-
ber of clinical grade BM-MSCs for cell therapy. BM-MSCS
are known to secrete a number of angiogenic factors and
have shown to form capillary like structures in an in vitro
matrigel assay [15]. They also suppress lymphocyte
alloreactivity in mixed lymphocyte cultures [16-18]. Be-
cause of their anti-inflammatory, immunosuppressive
properties and their ability to secrete paracrine factors,
BM-MSCs have been shown to be therapeutically effective
in patients suffering from peripheral vascular disease.
The primary objective of this study was to determine the
safety of allogeneic BM- MSCs in patients CLI by intra-
muscular administration. The secondary objective was to
assess the efficacy of this treatment in patients with CLI.
Methodology
Study design
This was a phase I/II randomized, double – blind,
placebo – controlled, multi-center trial. The studyconformed to the Declaration of Helsinki and followed
International Conference on Harmonization (ICH) –
Good Clinical Practice (GCP) guidelines and was
conducted with accordance to “Guidelines for Stem Cell
Research and Therapy” by Department of Biotechnology
and Indian Council of Medical Research (ICMR), 2007.
The protocol was approved by Drug Controller General
of India (Indian Food and Drug Administration) and by
the Institutional Ethical Committees of the four partici-
pating hospitals in India. An Independent Data Safety
Monitoring Board (DSMB) was established to assess the
progress of this study and reviewed the safety data at
periodic intervals. The study was registered in the
NIH website (Clinical trials.gov website; http://www.
clinicaltrials.gov/ct2/show/NCT00883870).
Criteria for enrolment
Patients with established CLI who had failed or were not
eligible for traditional revascularization procedure were
selected (Table 1). Informed consent was obtained from
all patients prior to any study related activity. The detail
of the total patients screened, allocated in each arm,
were followed up and analyzed in the trial is given in
Figure 1 (diagram as per the Consolidated Standards of
Reporting Trials (CONSORT) flow chart).
Preparation of investigational medicinal product
(BM-MSC) and placebo suspension
The Investigational Medicinal Product (IMP) was BM-
MSCs which obtained from bone marrow aspirates from
healthy donors who were not HLA matched to the re-
cipients. The volunteers for bone marrow donation were
tested according to 21 Code of Federal Regulations
(CFR) 640, FDA donor suitability & ICMR guidance for
healthy bone marrow donor screening. Mesenchymal
stem cells are isolated from the donor’s bone marrow
mononuclear stem cells using density gradient separ-
ation method and cultured. The cells were expanded
in vitro to manufacture the required number of cells. In
the process, a donor master cell bank was maintained,
which consists of cells cryopreserved in early passage
which served as a source of MSCs for future manufactur-
ing purpose. Also, a working cell bank was maintained for
routine upscaling and quality control purposes. The work-
ing cell bank was upscaled further to produce the IMP at
passage 4 which was used for the clinical trial. The IMP
specification is given in Table 2.
Once, the desired numbers of cells have been pro-
duced, aliquots of samples were provided for quality
control testing purposes. These include complete
characterization by flow cytometry and differentiation
capacity of these cells to osteocytes, chondrocytes and
adipocytes. In addition, sterility, mycoplasma and endo-
toxin testing were performed at the level of MCB, WCB
Table 1 Eligibility criteria for patients enrolled in the study
• Inclusion criteria Exclusion criteria
• Males or females with non-child bearing potential in the age group
of 18–60 yrs. of Indian origin.
• Patients with CLI suitable for surgical or percutaneous
revascularization as determined by the surgeon performing vascular
procedure and patients with any acute/chronic inflammatory
condition.
• Established CLI, clinically and hemodynamically confirmed as per
Rutherford- II-4, III-5, or III-6; Patients having Infra-inguinal arterial
occlusive disease with rest pain or ischemic ulcer/necrosis, who are
not eligible for or have failed traditional revascularization treatment
(No option patients).
• CLI patient requiring amputation proximal to trans-metatarsal level.
• Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm
Hg or TcPO2 ≤ 60 mmHg in the foot.
• Patients with gait disturbance for reasons other than CLI.
• Patients if having associated Type II Diabetes should be on
medication and well controlled (HbA1c ≤ 8%) without complications.
• Type I diabetes.
• Patients having respiratory complications/left ventricular ejection
fraction < 25% Stroke or myocardial infarction within last 3 months.
• Patients who are contraindicated for MRA
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microbial contaminants and were sterile.
Flow cytometry of BM-MSCs
For flow cytometry analysis of the surface molecule ex-
pression of BM-MSCs, the following monoclonal anti-
bodies (Mabs) directly conjugated with fluorochromesAssessed for 
Analysed (n=9)
Excluded from analysis (did not have even a  
single post-injection follow-up data) (n=1)
Lost to follow-up (Fatal SAE) (n=2)
Allocated to MSC (n=10) 






Figure 1 Total patients screened, allocated in each arm, followed up
of Reporting Trials (CONSORT) flow chart.were used: For MSC detection, CD 73-PE, CD 90-PE,
CD 166-PE (Becton Dickinson, San Diego, USA) and CD
106-PE (R&D Systems, Minneapolis, USA) (positive
markers {>85% positive}), while for hematopoietic cells,
CD 34-PE, CD 45-FITC, CD14-FITC, CD19-FITC, HLA-
DR-FITC (Becton Dickinson, San Diego, USA) and
CD133-PE (Miltenyi Biotec, Gladbach, Germany) (negativeeligibility (n=28)
Excluded (n=8)
Not meeting inclusion criteria (n=8)
Lost to follow-up (n=0)
Allocated to Placebo (n=10) 






and analyzed in the trial. Diagram as per the Consolidated Standards
Table 2 Investigational Medicinal Product (IMP)
specification
Description Specifications
Morphology Cells are fibroblastic and spindle shaped in active
growing condition.
Cells are intact and round in shape after the
trypsin action
Cell count 180 to 220 million cells per bag
Viability > 85%
Cell phenotype CD 73 > 80% CD 34 < 5%
CD105 > 80% CD 45 < 5%
CD 90 > 80% CD 133 < 5%
CD 166 > 80% CD 14 < 5%
CD19 < 5%
HLA-DR < 5%
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coated with conjugated Mabs at room temperature for
30 mins, washed, and fixed with 1% paraformaldehyde.
Next the cells were analyzed using an Easycyte Bench top
flow cytometer (Guava Technologies, Millipore, MA) using
Gauva Express Pro Software (Version 5.2).
Release criteria of the BM-MSC product
Aliquots of the cells were transferred into liquid nitro-
gen storage vials for quality testing. Release criteria for
BM - MSC administration were based on the following:
(1) negative results for microbiological testing, (2) endo-
toxin content of < 0.06 EU/ml, (3) cell viability (trypan
blue exclusion test) of > 85%, (4) pH between 7.2 to 7.4,
(4) Exhibiting normal DNA ploidy (5) Normal Karyotype
(6) Phenotypic marker analysis by flow cytometry as
above and (7) confirmation of differentiation of cells to
osteocyte, chrondocyte and adipocyte.
Infusion parameters & treatment groups
200 million BM-MSCs in 15 ml cryopreservation medium
or 15 ml PlasmaLyte A in the cryocyte bag (placebo) were
thawed and re-suspended in 35 mL of PlasmaLyte A
resulting in 50 mL of suspension. The IMP administration
was performed under IV sedation by Midazolam and
Fentanyl (12 patients) or under spinal/epidural anesthesia
(8 patients) and cardio-respiratory monitoring. The con-
stituted volume of the suspension was injected intramus-
cularly into the gastrocnemius muscle of ischemic lower
limb (40 – 60 sites, distributed in an area of 10 cm× 6 cm,
1 – 1.5 cm in depth and 0.5 ml - 1.0 ml of BM-MSCs or
placebo per site) by blinded 3 ml syringes. During the dos-
ing, oxygen saturation was monitored 30 min prior to and
6 hrs post injection of BM-MSCs/placebo. Investigators
were instructed to stop the injection if the patient showed
tachypnea, cyanosis, breathlessness, or if oxygen satur-
ation decreased to less than 85%. The patients remainedin the clinical facility under supervision for at least
24 hours post IMP administration. On discharge, patients
were given standard protocol of care for CLI as per inves-
tigator’s discretion. This included but not limited to anal-
gesics, antiplatelets and anticoagulants.
A total of 28 patients were screened for enrollment in
the trial, of which 20 subjects were included in the
study, 10 patients each in the BM-MSC arm and placebo
group respectively. All twenty patients in each of the
cohorts met identical inclusion and exclusion criteria.
Block randomization was conducted in a centralized
manner and communicated to the Investigational Med-
ical Product Management Team. Subjects were ran-
domly assigned in a double-blind fashion to each group
in a 1:1 ratio of BM-MSC arm to placebo. A total of five
patients had presented only with rest pain (3 in BM-
MSC arm and 2 in placebo arm), 10 patients presented
with minor tissue loss (5 each in BM-MSC and placebo
arm) and 5 patients presented with major tissue loss (3
in BM-MSC arm and 2 in placebo arm) (Table 3). An
Independent Data Safety Monitoring Board (DSMB) was
established to assess the progress of this study. The
DSMB was comprised of Patient safety expert, Pharma-
covigiliance and Pharma regulatory expert, Vascular
surgeon and Statistician. They reviewed the safety data
at periodic intervals, and gave their recommendations
on whether to continue, modify or stop the trial. The
DSMB reviewed the safety data of first five patients at
the end of 1, 4 and 12 weeks after IMP administration
Clinical assessments
All clinical and laboratory data, for determining both
safety and efficacy parameters, were prospectively col-
lected, and follow – up visits were performed at 1 day be-
fore and 7 days, 4 weeks, 12 weeks, 24 weeks after IMP
administration. Further safety parameters were assessed
after 1 year and 2 year of administration of IMP. All pa-
tients have completed two year follow-up. The study pa-
rameters were unblinded after six months follow up.
Primary safety assessments included monitoring and re-
cording of all adverse events (AEs), and assessment of
electrocardiogram (ECG) parameters. Hematological and
biochemical values, regular vital sign measurements, and
physical examination reports were recorded in all cases.
The efficacy end points included – relief of rest pain,
healing of necrosis and ulceration, increase in ankle pres-
sure, increase in ankle brachial pressure index (ABPI) and
prevention of amputation in the target limb. Rest pain
scores on rating scales ranged from 0 of the best (com-
pletely resolved) and 4 points for the worst condition (se-
vere pain unresolved with paracetamol or non-steroidal
anti-inflammatory drugs) [19]. Healing of all necrosis and
ulcerations in the target limb was assessed by independent
physician and documented by photography at each visit.
Table 3 Demographic and baseline disease condition










Revascularization details Grade of
disease*
S001 Placebo 35 161 56 Past tobacco chewer 6 Right transfemoral proximal &
distal thromboembolectomy
with proximal tibial artery
III6
S004 Placebo 37 165 67.2 Ex-Smoker 24 No II4
S005 BM-MSC 40 171 70.2 Ex-Smoker 10 No III5
S007 BM-MSC 43 169 65 Ex-Smoker 48 Bypass surgery in left femoral artery II4
S008 Placebo 32 166 42 Ex-Smoker 24 No III5
S009 BM-MSC 46 169 60 Ex-Smoker 24 No III6
S010 BM-MSC 57 160 42 Ex-Smoker 48 Femoropopliteal bypass above the
knee
II4
S102 Placebo 45 174 72 Ex-Smoker 25 Right common femoral artery to
anterior tibial artery reversed
Gsv bypass
III5
S104 BM-MSC 44 159 63 Smoker 45 No III5
S106 Placebo 32 164 71 Ex-Smoker 23 No III5
S301 Placebo 43 167 62 Ex-Smoker 4 No III6
S302 BM-MSC 37 165 62 Ex-Smoker 20 No III6
S303 BM-MSC 53 172 69 Ex-Smoker 20 No II4
S304 Placebo 59 162 60 Ex-Smoker 15 No III6
S305 Placebo 57 167 70 Ex-Smoker 15 Right popliteal artery exploration II4
S306 BM-MSC 46 170 46 Ex-Smoker 20 No III5
S307 Placebo 54 165 50 Ex-Smoker 50 Femoropopliteal artery bypass above knee III5
S308 BM-MSC 41 157 50 Ex-Smoker 20 No III5
S402 BM-MSC 60 170 55 Ex-Smoker 23 Femoro - popliteal bypass III5
S403 Placebo 36 167 60 Ex-Smoker 5 No III5
*Grade of disease classified according to Rutherford criteria.
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to published protocol. The number of amputations was
counted at the end of the study, with a focus on any po-
tential adverse effects resulting from the BM-MSC admin-
istration during follow – up.
In addition to the routine safety laboratory parameters,
levels of a few pro inflammatory cytokines were mea-
sured to evaluate the immunological response of the
IMP, and they included – Interleukin – 2 (IL-2), Tumour
necrosis factor (TNF) - alpha, Interferon – gamma. The
estimation of these cytokines was performed by ELISA
kits (abcam, San Francisco, CA, USA) using serum sam-
ples. In addition, lymphocyte profile before and after
IMP injection at different time intervals was done by
flow cytometry in terms of CD4, CD8 and CD25.Data collection
All data were recorded on manual case record forms
(CRF) and verified by comparison with source documen-
tation by third – party medical monitors. Safetyassessments were performed based on the frequency of
AEs and on clinically significant abnormal laboratory
values. The AEs incidents are summarized as the num-
ber and percentage of subjects experiencing AE within
each treatment arm.Statistical methods
The SAS® package (SAS® Institute Inc., USA, Version
9.2) was used for statistical evaluation. All data are
presented as mean ± SD. Rest pain scale (+4 to 0) over
subsequent visits were analyzed and compared between
the two arms using Kruskal Wallis test. Statistical signifi-
cance was defined as a two-sided p-value < 0.05. For
ABPI, change from baseline to 6 months was analyzed
using an analysis of variance (ANOVA) model with fac-
tors for baseline, treatment and also compared between
the two arms using Kruskal Wallis test. Statistical signifi-
cance was defined as a two-sided p-value < 0.05. Num-
ber of amputations, healing of ulcer and necrosis were
summarized descriptively as the data was insufficient to











At least one symptom 6 (13) 7 (45)
Gastrointestinal disorders 1 (1) 2 (2)
General disorders and administration
site conditions
3 (3) 0
Hepatobiliary disorders 0 1 (1)
Infections and infestations 3 (3) 3 (3)
Injury, poisoning and procedural
complications
1 (1) 1 (2)
Investigations 1 (2) 3 (29)




Nervous system disorders 0 2 (3)
Psychiatric disorders 0 1 (1)
Renal and urinary disorders 1 (1)
Skin and subcutaneous tissue disorders 1 (1) 0
Vascular disorders 1 (2) 0
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were performed in the modified intent to treat (MITT)
set that included 19 patients.
Results
Characteristic of patients
Demographic and baseline patient data are listed in
Table 3. All the patients were of Peripheral arterial dis-
ease (PAD) and the underlying etiology was either due
to atherosclerosis or Thromboangitits Obliterans (TAO).
Out of a total of 28 patients screened, 20 patients were
randomized in the study from 4 centers. Of these, 18 pa-
tients completed the study and 2 patients (BM-MSC
arm) were withdrawn from the study due to fatal SAEs.
The SAEs were attributed to the progression of disease.
Procedural safety
No infection, bleeding, or other complications related to
the microbiological condition of the cells were detected
in any patient after administration of BM-MSC/placebo
which were well tolerated. There were no other proced-
ural related complications like allergic reactions or local
swelling because of intramuscular injection of the IMP
suggesting that the allogeneic BMMSCs were safe to in-
ject into the CLI patients.
AEs & SAEs
The total number of adverse events as classified by
MedDRA Primary System Organ Class and Preferred
Term recorded in the study was 58 (Table 4). There was
considerable difference in the overall incidence of AEs
between the two arms, with 13 AEs were reported by 6
patients in BM-MSC arm and 45 AEs in 8 patients in
the placebo arm (p = 0.6256). None of the AEs in the
BM-MSC arm were related to treatment.
Most of the AEs observed in the study were due to ab-
normal clinical laboratory values. One patient in BM-
MSC arm and 3 patients in placebo arm developed 2 and
23 laboratory abnormalities respectively. None of the ab-
normalities were attributed to the IMP administration by
the members of the DSMB and the Principal Investigators
(PI) of the study where the AEs were observed.
Fourteen SAEs (6 in BM-MSC arm and 8 in placebo
arm) were recorded because of hospitalization for dis-
ease process related complications. Two patients in BM-
MSC arm died during the course of the study: One
patient died within seven days of the BM-MSC adminis-
tration due to cardiac causes as determined by the
DSMB and the second patient died after five months of
BM-MSC administration due to progression of CLI with
ischaemic gangrene leading to amputation and septicae-
mia. It was concluded by the respective PIs and the
DSMB that the cause of the death was not due to IMP
administration.Laboratory investigations
Hematological, biochemical and urine analysis results
from patients in both treatment arms were comparable
at baseline and subsequent visits. Immunological profile
(IFN- gamma, IL - 1 & TNF – alpha levels) and lympho-
cyte profile (CD4, CD8 & CD25) performed at one month,
three months and six months after administration of IMP
or placebo, revealed that were comparable in both the
arms (Figure 2, Tables 5 and 6). No significant difference
in the blood lymphocyte profile or in the serum cytokine
level was observed between BM-MSC and placebo admin-
istered patients suggesting that the administered allogen-
eic cells did not elicit T-cells proliferative response in vivo,
as estimated for the values obtained for the various sub-
sets of T lymphocytes (Table 6). With respect to the levels
of the pro-inflammatory cytokines we observed a differ-
ence between the BM-MSC administered patients and the
placebo control patients at baseline, 1 month & 6 months
after treatment, but they were either comparable with the
baseline values or were within the normal range of these
cytokines (Table 5). Collectively, these data indicates that
allogeneic BM-MSC administration in CLI patients did
not adversely alter the immunological profile.
Clinical efficacy of allogeneic BM-MSC transplantation
1. ABPI & Ankle Pressure: ABPI and ankle pressure were
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at baseline (Table 7, Figure 3). A mean change of
0.22 was observed in ABPI in BM-MSC arm while
there was no change in the placebo arm from
baseline to 6 months (p = 0.0018). A mean change
of 18.96 mmHg was observed in ankle pressure inble 5 Summary of serum Cytokines values at screening, 1 mo
st Screening
BM-MSC arm Placebo BM-M
N = 10 N = 10 N
Mean (SD) Mean (SD) Mean
mma - Interferon (pg/ml) 24.4(13.35) 23.1(24.07) 37.8
terleukin - 1 (pg/ml) 22.6(14.73) 22.9(15.31) 33.1(
mor Necrosis Factor - alpha (pg/ml) 14.2(9.16) 13.8(10.11) 16.6the BM-MSC arm compared to 3.92 mmHg change
from baseline in the placebo arm (p = 0.047).
2. Rest Pain: Both the groups showed significant
improvements in rest pain score from baseline to
6 months (Table 7). The median change from
baseline to 6 months in rest pain score of BM-MSCnth & 6 month follow-up after BM-MSC implantation
1 month 6 months Normal range
(pg/ml)SC arm Placebo BM-MSC arm Placebo
= 9 N = 10 N = 7 N = 10
(SD) Mean (SD) Mean (SD) Mean (SD)
(34.35) 20(24.67) 9.1(6.34) 6.6(3.57) 0.01 - 168
23.59) 22.9(21.73) 26.6(29.28) 10(3.26) 0 - 400
(6.16) 15.7(7.98) 11.4(11.65) 4.4(2.47) 0 – 3.22
Table 6 Summary of lymphocyte profile values at screening, 1 month & 6 month follow-up after BM-MSC implantation
Test Screening 1 month 6 months
BM-MSC arm Placebo BM-MSC arm Placebo BM-MSC arm Placebo
N = 10 N = 10 N = 9 N = 10 N = 7 N = 10
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
CD4 (cells/μl) 923.1 (217.52) 856.3 (237.29) 905.6 (134.37) 922.4 (451.48) 1020.9 (405.67) 954.4 (164.49)
CD8 (cells/μl) 682.5 (253.96) 688.3 (420.36) 664.2 (183.02) 644.9 (396.27) 786.3 (329.27) 727.9 (312.25)
CD25 (cells/μl) 21.3 (22.22) 16.3 (10.92) 21.7 (14.34) 22.0 (20.66) 30.3 (25.36) 35.3 (28.04)
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(p = 0.1099).
3. Ulceration: At the time of recruitment 13 patients
reported having one or more ulcers, 7 patients in
the BM-MSC arm and 6 patients in the placebo
arm. At two year follow-up, one patient in the BM-
MSC arm continued to have ulcer, however the size
of the ulcer decreased, whereas all ulcers healed in
placebo arm.
4. Amputation: Four patients (2 in each arm) were
identified for toe amputations at screening (pre-
planned amputations). During the study, another 5
amputations (three in the BM-MSC arm and two in
the placebo arm) were conducted. This included
four above knee amputations (2 in each arm), and
one toe amputation in the BM-MSC arm. The
number and level of amputations were similar in
both the treatment arms. The small numbers
precluded a reasonable statistical analysis.
Discussion
To our knowledge, this is the first randomized, double –
blinded, placebo controlled multicenter phase I/II trial
to assess primarily the safety and also the potential ef-
fects of intramuscular allogeneic BM-MSC administra-
tion in patients with critical limb ischemia. Our results
highlight the safety of using allogeneic bone marrow de-
rived MSCs in patients with CLI and showed positive
trends towards improvement as evidenced by the in-
crease in parameters such as ankle pressure and ABPI,
consistent with previous reports on cell based therapies
in CLI [20-23]. However, patients with impending ampu-
tation did not derive any benefit from BM-MSC admin-
istration. This group of patients had a poor prognosis,
due to the advanced disease process and the clinical
outcome was predetermined. For this study, CLI wasTable 7 Efficacy parameters
BM-MSC arm
Baseline 6 months B
Rest pain (Median) 3 1
ABPI Mean (SD) 0.554 (0.26) 0.768 (0.15) 0.
*Kruskal-Wallis test.
ANOVA.determined by an ankle pressure of ≤ 70 mmHg along
with that of ABPI of ≤ 0.6. Both these parameters
showed significant improvement in patients included in
the BM-MSC arm while this was not the case in patients
treated with placebo (p < 0.05).
Pooled analyses from different studies conducted using
stem cells in CLI have shown that ABPI increased be-
tween 0.1 and 0.2 points and a TcPO2 increase between
10 and 20 mmHg [24]. The randomized, double – blind,
placebo – controlled PROVASA (Intra-arterial progeni-
tor cell transplantation of bone marrow mononuclear
cells for induction of neovascularization in patients with
peripheral arterial occlusive disease) study showed no
significant difference in the primary outcome of im-
provement in ABPI [25]. However, there were significant
improvements in other secondary end points, including
ulcer healing and rest pain reduction in the BM-MSC
arm group. The authors debated that ABPI was a poor
selection as a primary end point. In a recently completed
Investigator led trial, we have shown that intra-arterial
administration of allogeneic BM-MSCs resulted in sig-
nificant decrease in pain score (VAS score), ABPI and
TcPO2 parameters [26]. It also showed complete ulcer
healing to 70% reduction in ulcer area as compared to
the baseline values. The TACT trial [23] (therapeutic
angiogenesis by cell transplantation) also reported that
autologous BM-MNC administration did not alter the
ABPI and TcPO2 in patients with atherosclerotic PAD
or patients with Buerger’s disease over a period of
3 years, however led to improvement of other efficacy
parameters such as extension of amputation free interval
and improvement of ischemic rest pain. They concluded
that ABPI value is not a useful predictor for evaluating
the long – term efficiency of the angiogenic therapy
using bone marrow cells. In a previous TACT trial [19]
and in our published study [26] ABPI and TcPO2 valuesPlacebo
aseline 6 months Difference P value
3 0 −1.00 0.1099*







































Figure 3 Efficacy parameters: Results of ABPI & Ankle pressure
are shown as mean ± SD and corresponding p values. V1:
screening; V4: 1 month; V5: 3 month; V6: 6 month follow – up.
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otic PAD at 4 and 24 weeks. In another study, Idei et al.
[27] reported an increase in ABPI and TcPO2 after BM-
MNC implantation in patients with atherosclerotic PAD
and Buerger’s disease. In Buerger’s disease, ABPI and
TcPO2 were significantly increased after 1 month and
remained high during the 3 – year follow – up period.
However, in patients with PAD, ABPI and TcPO2 pres-
sure increased significantly after 1 month and gradually
decreased during the follow – up, and, returned to the
base line values at the end of 3 – year follow – up
period. The differences in the severity of PAD may in
part explain the observed differences in changes in per-
fusion between these studies.
We observed decrease in subjective rest pain in all pa-
tients irrespective of the arms they belonged to. This
may partially be explained by the sufficient concomitant
analgesics administered; however, the intake of analge-
sics was not analyzed objectively. We included patients
with diabetes mellitus type 2, which might have caused
similar outcomes of rest pain due to the decreased sensi-
tivity of pain with diabetic peripheral neuropathy which
was also reported in a study published by Lu et al. [28].
Furthermore, other published studies which showed im-
provements in rest pain in the BM-MSC arm measuredthe rest pain score on the Visual Analogue Scale (VAS)
of 0 to 10 [20,27] which was not followed in our study.
The adverse events in the BM-MSC arm were less as
compared to the placebo. Most of the adverse events
were abnormal clinical laboratory values and or symp-
toms related to the progression of the disease. One pa-
tient in the BM-MSC arm died suddenly within one
week of IMP administration. DSMB and the Indian FDA
did an audit of the patient records, his past history and
concluded that the sudden death was not related to IMP
and the likely cause of death was a sudden cardiac event,
which is not uncommon in patients with CLI [29]. Most
studies have shown that cell therapy is promising for
angiogenesis and has no severe adverse effects in patients
afflicted with Buerger’s disease [19], [30-32]. However, pa-
tients with atherosclerotic PAD may have increased mor-
tality due to associated cardiovascular risk factors.
Ulcer healing and amputation rates were similar in
both arms in our study. This may be due to the fact that
these critically ill patients with impending amputation
due to the advanced nature of the disease did not derive
much benefit from allogeneic BM-MSC administration.
In a study by Walter et al. [25] all 4 patients with exten-
sive gangrene with impending amputation (Rutherford
class 6) at inclusion in the study had to undergo ampu-
tation above the ankle during the initial 3 month period.
There are few published reports on clinical trial results
using autologous or allogeneic BM-MSCs in CLI since
majority of the reported trials used autologous BM-
MNCs. The mechanism through which MSCs exerts
angiogenesis is mainly by secreting angiogenic growth
factors or cytokines and also through differentiation into
endothelial cells [33,34]. The pro-angiogenic effect of
MSC has been demonstrated in several studies both
in vitro and in vivo [33,34]. MSCs have been shown to ex-
press and secrete stromal cell-derived factors - 1 (SDF-1),
vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF); matrix metalloproteinases (MMPs),
all of which are important for triggering and maintaining
angiogenesis [35]. However, apart from their angiogenic
activity, MSCs obtained from bone marrow and other tis-
sues have also been shown to mediate anti-inflammatory,
anti-apoptotic, anti-fibrotic, mitogenic and wound healing
properties [36].
Many clinical trials are using autologous BMMNCs for
evaluating the efficacy in PAD patients but it has many
limitations. Firstly, the active cellular constituent of bone
marrow that is the agent of repair is not well character-
ized. Secondly, it is widely accepted that therapeutically
active bone marrow constituents likely represents only 1
in 10,000 bone marrow cells [37]. Thirdly, aspiration of
the bone marrow is an invasive process and lastly, con-
cerns exist that patients most likely to be affected by
atherosclerosis are also likely to have impaired marrow
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important advantages. They are likely to represent an
enriched population of cells with therapeutic angiogenic
capacity. They are readily prepared from healthy donors
and may be used as an allogeneic, “off – the - shelf”
cryopreserved product [39] without HLA matching be-
cause of their hypoimmunogenic, immunosuppressive
and immunomodulatory properties.
Although this is a small study performed with a small
number of patients (20), it offers some potential clinical
insights. As the primary goal of the study, potential safety
concerns are alleviated by our findings. Delivery of the
BM-MSC via the IM route (in this study) or our earlier
published study by IA route [26] did not compromise, ra-
ther appeared to have improved the hemodynamic param-
eters in the lower limbs of the treated patients. This work
also forms the basis for future clinical trials aimed at
establishing the therapeutic possibility of using allogeneic
BM-MSCs in CLI patients to improve angiogenesis and
increasing amputation – free survival in these patients.Conclusion
This study was conducted to assess the safety of allo-
geneic BM-MSCs in no – options patients in CLI, and
utilized a rigorous double – blind, placebo – controlled,
study design. The study met its primary objective of
safety with regard to use of allogeneic BM-MSCs for the
treatment of CLI. Few of the efficacy parameters showed
significant improvements like ABPI and ankle pressure
in the BM-MSC arm patients. Our findings support the
conduct of more extensive studies with a larger group of
patients for assessing the therapeutic efficacy of using
allogeneic BM-MSCs for the treatment of vascular
disorders.
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